Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and
Phase I evaluation of vindesine in children: A southwest oncology group pilot study
✍ Scribed by Komp, Diane ;Vats, Tribhawan ;Shepherd, Dell A. ;Vietti, Teresa ;Hoogstraten, Barth ;Haas, Charles D.
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 374 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Twenty‐one children (19 with leukemia) were given 34 courses of vindesine on a weekly or twice‐weekly schedule in escalating doses. Thirty‐three courses were fully or partially evaluable for response and/or toxicity. Granulocyto‐penia was the dose‐limiting toxicity. Transient jaw, neck, or bone pain was common after each dose. Motor weakness, paresthesias, and constipation were neither frequent nor severe. In this Phase I study, vindesine had some antileu‐kemia activity in children previously treated with vincristine and other drugs. Phase II studies are warranted and a starting dose of 1.85 mg/m^2^ twice weekly appears tolerable.
📜 SIMILAR VOLUMES
## Abstract A phase II evaluation of DAG in head and neck cancer patients produced one partial response and one patient with prolonged stable disease from nine fully evaluable patients with squamous carcinomas. One partial response was produced in a patient with anaplastic thyroid carcinoma. No dru
## Abstract ## BACKGROUND The objective of this study was to estimate the time to treatment failure and survival rate of the three‐drug combination of doxorubicin, cisplatin, and ifosfamide as primary and postoperative, adjunctive treatment for teenagers and adults with osteosarcoma (OS). ## METH